United Therapeutics Corporation (Wed, Apr 24, 2024)

Sell candidate since Apr 22, 2024 Gain 1.26%

StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania



score: **-2.33** #14003/ 30099

Trend:	Buy
MV Long:	Sell
MV Short:	Buy
Pivot:	Sell
Volume:	Buy
MACD:	Buy

I

Tech commentaries:

The **United Therapeutics Corporation** stock price gained **1.08%** on the last trading day (Wednesday, 24th Apr 2024), rising from **\$234.47** to **\$237.00**. During the last trading day the stock fluctuated **3.16%** from a day low at **\$233.61** to a day high of **\$241.00**. The price has risen in 6 of the last 10 days but is still down by **-0.33%** for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **174 thousand** more shares were traded than the day before. In total, **574** thousand shares were bought and sold for approximately **\$136.05** million.

The stock lies in the lower part of a wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at \$234.25 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise **11.74%** during the next 3 months and, with a 90% probability hold a price between **\$261.76** and **\$294.28** at the end of this 3-month period.

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **United Therapeutics Corporation** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at **\$237.18**. On a fall, the stock will find some support from the short-term average at **\$235.35**. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on **Monday, March 11, 2024**, and so far it has fallen -5.01%. Further fall is indicated until a new bottom pivot has been found.

United Therapeutics Corporation finds support from accumulated volume at \$235.78 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at **\$237.24**, **\$243.27** and **\$244.26**.

This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low. During the last day, the stock moved **\$7.39 (3.16%)** between high and low. For the last week, the stock has had daily average volatility of **2.39%**.

United Therapeutics Corporation holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Risk: Low

Evaluation: Sell Candidate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.